Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Use of cfDNA and exovesicle-DNA for the molecular diagnosis of chronic Chagas disease

View ORCID ProfileNoelia Lozano, Mercedes Gomez Samblas, Eva Calabuig, María José Giménez Martí, Maria Dolores Gómez Ruiz, José Miguel Sahuquillo Arce, José Miguel Molina Moreno, View ORCID ProfileM. Trelis, View ORCID ProfileAntonio Osuna
doi: https://doi.org/10.1101/2023.02.24.23286400
Noelia Lozano
1Area of Parasitology. Department of Pharmacy and Pharmaceutical Technology and Parasitology. University of Valencia. 46010 Valencia, Spain
2Servicio de Microbiología y Parasitología Clínica. Hospital Universitario y Politécnico La Fe-IIS La Fe, 46010 Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noelia Lozano
Mercedes Gomez Samblas
3Grupo de Bioquímica y Parasitología Molecular (CTS 183), Departamento de Parasitología, Campus de Fuentenueva, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aosuna{at}ugr.es msambla{at}ugr.es
Eva Calabuig
4Unidad de Enfermedades Infecciosas. Servicio de Medicina Interna. Hospital Universitario y Politécnico La Fe-IIS La Fe. Valencia 46010, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María José Giménez Martí
2Servicio de Microbiología y Parasitología Clínica. Hospital Universitario y Politécnico La Fe-IIS La Fe, 46010 Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Dolores Gómez Ruiz
2Servicio de Microbiología y Parasitología Clínica. Hospital Universitario y Politécnico La Fe-IIS La Fe, 46010 Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Miguel Sahuquillo Arce
2Servicio de Microbiología y Parasitología Clínica. Hospital Universitario y Politécnico La Fe-IIS La Fe, 46010 Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Miguel Molina Moreno
2Servicio de Microbiología y Parasitología Clínica. Hospital Universitario y Politécnico La Fe-IIS La Fe, 46010 Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Trelis
1Area of Parasitology. Department of Pharmacy and Pharmaceutical Technology and Parasitology. University of Valencia. 46010 Valencia, Spain
5Joint Research Unit on Endocrinology. Nutrition and Clinical Dietetics, University of Valencia-Health Research Institute La Fe, Valencia 46010, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Trelis
Antonio Osuna
3Grupo de Bioquímica y Parasitología Molecular (CTS 183), Departamento de Parasitología, Campus de Fuentenueva, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio Osuna
  • For correspondence: aosuna{at}ugr.es msambla{at}ugr.es
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Chagas disease is, among others, considered a neglected tropical disease. Given the magnitude of the human movements that have occurred in recent years from Central and South America to other countries, Chagas should now be considered a disease of worldwide distribution, in which the transmission of the parasite is restricted to transplacental transmission or blood or organ donations from infected people.

Parasite detection in chronically ill patients is restricted to serological tests that only determine previous contact and not the presence of the parasite, especially in those patients undergoing treatment evaluation or in newborns.

In this study, we evaluate the use of nucleic acids from both circulating serum exovesicles and cell-free DNA (cfDNA) from 448 serum samples from immunologically diagnosed chronic chagasic patients, which were re-evaluated by nested PCR on the amplicons resulting from amplification with kDNA-specific primers 121F-122R. Of the total number of samples selected, 50 were used to isolate and purify exovesicles from circulating serum and cell-free DNA (cfDNA).

When the nucleic acids thus purified were assayed as a template and amplified with primers 121F-122R and SAT, a percentage positivity of 100% was obtained for all positive samples assayed with the kDNA-specific primers and 96% when SAT primers were used. However, isolation of cfDNA for T. cruzi and amplification with SAT primers also showed 100% positivity. Hence, both samples can be used in those cases where it is necessary to demonstrate the active presence of the parasite.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

University of Granada 201102400000408 and 672/CEIH/2018

Funding Statement

This research was funded by the ERANET program, Research in prevention of congenital Chagas disease parasitological, placental and immunological markers ERANET17 HLH 0142. Instituto Carlos III, Ministerio de Sanidad, Gobierno de Spain. Fundacion Ramon Areces Interactoma de las exovesiculas de T. cruzi y de los inmunocomplejos que forman con las celulas del hospedador: implicaciones en la patologia de la enfermedad de Chagas 2019. Ministerio de Ciencia y Tecnologia of the government of Spain funded the project PGC2018 099424 BI00 and The financial support given by the project ABIO 350 UGR18 Proyect Programa Operativo FEDER de Andalucia JJAA 2014 2020

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All of the patients gave written informed consent before starting the study and all protocols were approved on March 4, 2011, the study was expanded to include the use to isolate and purify exovesicles from circulating serum and cell-free DNA (cfDNA) on September 26, 2018, with registration numbers 201102400000408 and 672/CEIH/2018 respectively, by the ethical committee of Granada University.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript in supplementary material

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 26, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Use of cfDNA and exovesicle-DNA for the molecular diagnosis of chronic Chagas disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Use of cfDNA and exovesicle-DNA for the molecular diagnosis of chronic Chagas disease
Noelia Lozano, Mercedes Gomez Samblas, Eva Calabuig, María José Giménez Martí, Maria Dolores Gómez Ruiz, José Miguel Sahuquillo Arce, José Miguel Molina Moreno, M. Trelis, Antonio Osuna
medRxiv 2023.02.24.23286400; doi: https://doi.org/10.1101/2023.02.24.23286400
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Use of cfDNA and exovesicle-DNA for the molecular diagnosis of chronic Chagas disease
Noelia Lozano, Mercedes Gomez Samblas, Eva Calabuig, María José Giménez Martí, Maria Dolores Gómez Ruiz, José Miguel Sahuquillo Arce, José Miguel Molina Moreno, M. Trelis, Antonio Osuna
medRxiv 2023.02.24.23286400; doi: https://doi.org/10.1101/2023.02.24.23286400

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)